Liraglutide
Liraglutide is a first-generation GLP-1 receptor agonist with FDA approvals for Type 2 diabetes and weight management, yet off-label community use clusters overwhelmingly on appetite suppression and weight loss, with blood sugar control a distant second. Clinician protocols fix on 3 mg injected subcutaneously each morning and run continuously, while the captured corpus shows roughly three-quarters of 101 weight-loss reports rating positive, against single-digit reporting for blood sugar. The off-label evidence base is thinner than the discourse suggests, and most exploratory indications carry no posted results.
Research Evidence
Evidence shape
The evidence base is high-tier: the strongest trials support liraglutide for Type 2 diabetes and obesity, with 83 blinded studies posting results across 137 sponsors. Depth is concentrated—only 15 of 117 mapped indications carry posted results, while 85 single-trial indications and exploratory areas such as NAFLD, PCOS, and osteoarthritis remain thin. Conditions including chronic kidney failure and psoriatic arthritis show no posted data; the gap between mapped indications and verified outcomes is substantial.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Liraglutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
329 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- BID
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 3 mg BID subQ (1 source).
- Frequency
- unspecified
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Community reports indicate overwhelming positive experiences with Liraglutide, particularly for weight loss and appetite control (81.4% positive from 97 reports) and blood sugar control/Type 2 Diabetes (100% positive from 6 reports). Specific dosing details are not consistently reported in anecdotal accounts.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Pancreatitis : Postmarketing reports, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed . Never share a liraglutide injection pen between patie…
- • Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with liraglutide injection r…
- • Acute Kidney Injury : Postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration which may sometimes require hemodialysis. Use caution when initiating or escalating doses of liraglutide injection in patients with renal impairment .
- • Hypersensitivity Reactions : Postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) . Discontinue liraglutide injection and promptly seek medical advice .
- • Acute Gallbladder Disease : If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated .
- • Pulmonary Aspiration During General Anesthesia or Deep Sedation : Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
- • Liraglutide injection is contraindicated in
- • patients with a: personal or family history of medullary thyroid carcinoma (MTC) or in
- • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . serious hypersensitivity reaction to liraglutide or to any of the excipients in liraglutide injection. Serious h…
- • Patients with a personal or family history of medullary thyroid carcinoma or in
- • patients with Multiple Endocrine Neoplasia syndrome type 2 .
- • Patients with a serious hypersensitivity reaction to liraglutide or any of the excipients in liraglutide injection .
- • Effects of delayed gastric emptying on oral medications: Liraglutide injection delays gastric emptying and may impact absorption of concomitantly administered oral medications (7) .
Peptide feedback
0 forum repliesLive community discussion for Liraglutide, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.